Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 200
Filter
1.
Int J Radiat Oncol Biol Phys ; 51(3): 571-8, 2001 Nov 01.
Article in English | MEDLINE | ID: mdl-11597795

ABSTRACT

PURPOSE: A multi-institutional, prospective, randomized trial was undertaken in patients with advanced head-and-neck squamous cell carcinoma to address (1) the validity of using pathologic risk features, established from a previous study, to determine the need for, and dose of, postoperative radiotherapy (PORT); (2) the impact of accelerating PORT using a concomitant boost schedule; and (3) the importance of the overall combined treatment duration on the treatment outcome. METHODS AND MATERIALS: Of 288 consecutive patients with advanced disease registered preoperatively, 213 fulfilled the trial criteria and went on to receive therapy predicated on a set of pathologic risk features: no PORT for the low-risk group (n = 31); 57.6 Gy during 6.5 weeks for the intermediate-risk group (n = 31); and, by random assignment, 63 Gy during 5 weeks (n = 76) or 7 weeks (n = 75) for the high-risk group. Patients were irradiated with standard techniques appropriate to the site of disease and likely areas of spread. The study end points were locoregional control (LRC), survival, and morbidity. RESULTS: Patients with low or intermediate risks had significantly higher LRC and survival rates than those with high-risk features (p = 0.003 and p = 0.0001, respectively), despite receiving no PORT or lower dose PORT, respectively. For high-risk patients, a trend toward higher LRC and survival rates was noted when PORT was delivered in 5 rather than 7 weeks. A prolonged interval between surgery and PORT in the 7-week schedule was associated with significantly lower LRC (p = 0.03) and survival (p = 0.01) rates. Consequently, the cumulative duration of combined therapy had a significant impact on the LRC (p = 0.005) and survival (p = 0.03) rates. A 2-week reduction in the PORT duration by using the concomitant boost technique did not increase the late treatment toxicity. CONCLUSIONS: This Phase III trial established the power of risk assessment using pathologic features in determining the need for, and dose of, PORT in patients with advanced head-and-neck squamous cell cancer in a prospective, multi-institutional setting. It also revealed the impact of the overall treatment time in the combination of surgery and PORT on the outcome in high-risk patients and showed that PORT acceleration without a reduction in dose by a concomitant boost regimen did not increase the late complication rate. These findings emphasize the importance of coordinated interdisciplinary care in the delivery of combined surgery and RT.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Head and Neck Neoplasms/radiotherapy , Head and Neck Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Combined Modality Therapy , Female , Head and Neck Neoplasms/pathology , Humans , Male , Middle Aged , Mouth Mucosa/radiation effects , Neoplasm, Residual , Postoperative Period , Prospective Studies , Radiation Injuries/etiology , Risk , Survival Rate , Time Factors
2.
Med Care ; 39(11): 1217-23, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11606875

ABSTRACT

OBJECTIVES: To assess the 1- and 2-year health status, health care utilization and self-efficacy outcomes for the Chronic Disease Self-Management Program (CDSMP). The major hypothesis is that during the 2-year period CDSMP participants will experience improvements or less deterioration than expected in health status and reductions in health care utilization. DESIGN: Longitudinal design as follow-up to a randomized trial. SETTING: Community. PARTICIPANTS: Eight hundred thirty-one participants 40 years and older with heart disease, lung disease, stroke, or arthritis participated in the CDSMP. At 1- and 2-year intervals respectively 82% and 76% of eligible participants completed data. MAIN OUTCOME MEASURES: Health status (self-rated health, disability, social/role activities limitations, energy/fatigue, and health distress), health care utilization (ER/outpatient visits, times hospitalized, and days in hospital), and perceived self-efficacy were measured. MAIN RESULTS: Compared with baseline for each of the 2 years, ER/outpatient visits and health distress were reduced (P <0.05). Self-efficacy improved (P <0.05). The rate of increase is that which is expected in 1 year. There were no other significant changes. CONCLUSIONS: A low-cost program for promoting health self-management can improve elements of health status while reducing health care costs in populations with diverse chronic diseases.


Subject(s)
Chronic Disease , Disease Management , Outcome Assessment, Health Care , Patient Education as Topic , Self Care , Adult , Aged , Chronic Disease/economics , Community Health Services/statistics & numerical data , Cost-Benefit Analysis , Female , Health Status , Humans , Longitudinal Studies , Male , Matched-Pair Analysis , Middle Aged , Self Efficacy
3.
J Gerontol A Biol Sci Med Sci ; 56(8): M465-70, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11487597

ABSTRACT

BACKGROUND: Despite well-known benefits of physical activity for older adults, about two thirds are underactive. Community-based programs are needed to facilitate increased physical activity. We examine the effectiveness of CHAMPS II, an inclusive, choice-based physical activity promotion program to increase lifetime physical activity levels of seniors. CHAMPS guided participants to choose activities that took into account their health, preferences, and abilities. It offered information on ways for them to exercise safely, motivate themselves, overcome barriers, and develop a balanced exercise regimen. METHODS: A 1-year randomized controlled trial was conducted with physically underactive seniors in a multispecialty group practice. Changes in self-reported physical activity by group were evaluated using ANCOVA, controlling for age and sex. RESULTS: Of 173 randomized subjects, 164 (95%) completed the trial. Subjects were aged 65 to 90 years (M = 74, SD = 6); 66% were female. The intervention group increased estimated caloric expenditure by 487 calories/week in moderate (or greater) intensity activities (MET >/= 3.0; p <.001) and by 687 calories/week in physical activities of any intensity (p <.001). Control group changes were negligible. Between-group analyses found that the changes were significantly different in both measures (p values <.05). Overweight persons especially benefited from this program. The program was as effective for women, older adults (75+), and those who did not set aside time to exercise at baseline. CONCLUSIONS: The program led to meaningful physical activity increases. Individually tailored programs to encourage lifestyle changes in seniors may be effective and applicable to health care and community settings.


Subject(s)
Community Health Services/organization & administration , Exercise , Health Promotion/methods , Life Style , Aged , Aged, 80 and over , California , Female , Follow-Up Studies , Humans , Male , Multivariate Analysis , Probability , Program Evaluation , Reference Values , Sensitivity and Specificity , Treatment Outcome
4.
Cancer ; 92(2): 225-31, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11466673

ABSTRACT

BACKGROUND: Breast carcinoma and thyroid carcinoma are two malignancies that occur most commonly in women. An association between the incidence rates of thyroid and breast carcinoma in women after a diagnosis of the other malignancy has been suggested in a retrospective analysis of a single institution's tumor registry. In that study, an increased incidence of breast carcinoma in premenopausal women previously treated for thyroid carcinoma was observed. METHODS: The purpose of this study was to investigate further this relation utilizing a large database, the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database. The SEER database is maintained by the National Cancer Institute, and it represents 11 population-based cancer registries covering approximately 14% of the United States population. The study was a population-based retrospective cohort analysis using external comparisons. From 1973 to 1994, 365 women in the SEER database were identified as having both thyroid and breast carcinomas. The SEER database from 1973 to 1994 was utilized to calculate age specific and calendar year specific incidence rates for each year for thyroid and breast carcinomas. The expected number of second cancers for each age group, calendar year, and follow-up period were determined by multiplying these incidence rates by the age specific and calendar year specific number of person-years at risk. The risk ratio (RR) was calculated by dividing the observed by the expected number of second cancers. Statistical significance was determined by the Poisson test. RESULTS: A total of 1,333,115 person-years were available for analysis. One hundred thirteen thyroid carcinoma cases were diagnosed after breast carcinoma cases (RR, 0.99; P = 0.576). Two hundred fifty-two breast carcinoma cases were diagnosed after thyroid carcinoma cases (RR, 1.18; P = 0.007). Premenopausal women (age 20-49 years) with an index thyroid carcinoma have a significantly increased risk of developing subsequent breast carcinoma (RR, 1.42; P = 0.001). Black premenopausal women with an index thyroid carcinoma do not have an increased risk of developing breast carcinoma, but the statistical power is lower due to low numbers. No women with index breast carcinoma have an increased risk of developing thyroid carcinoma. CONCLUSIONS: Women with a history of thyroid carcinoma have a greater than expected risk of developing breast carcinoma. This risk is most pronounced in premenopausal white women. The implications of this observation with respect to breast carcinoma screening guidelines and thyroid carcinoma treatment guidelines deserve further investigation.


Subject(s)
Breast Neoplasms/epidemiology , Breast Neoplasms/etiology , Carcinoma/complications , SEER Program , Thyroid Neoplasms/complications , Adult , Aged , Databases, Factual , Epidemiologic Studies , Female , Humans , Incidence , Middle Aged , Premenopause , Risk Factors , White People
5.
Biol Blood Marrow Transplant ; 7(5): 294-301, 2001.
Article in English | MEDLINE | ID: mdl-11400952

ABSTRACT

A retrospective analysis was performed to investigate the outcome of high-dose therapy (HDT) and autologous hematopoietic cell transplantation in patients with follicular lymphomas beyond first remission. Ninety-two patients with primary induction failure or relapsed follicular low-grade lymphoma (FLGL), follicular large cell lymphoma (FLCL), and transformed follicular lymphoma (TFL) were treated with myeloablative therapy consisting of etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and either carmustine (BCNU;15 mg/kg) or fractionated total body irradiation (FTBI; 1200 cGy) followed by transplantation of purged autologous bone marrow or peripheral blood hematopoietic cells. For the 49 patients with relapsed FLGL, the median age was 49 years and the median interval from diagnosis to HDT was 30 months. The 4-year estimate of overall survival (OS) was 60% (95% confidence interval [CI], 45%-75%) and of disease-free survival (DFS) was 44% (95% CI, 29%-59%). Treatment with the FTBI-containing HDT regimen was associated with significantly longer DFS (P = .04) and OS (P = .04) in our multivariate analysis. OS was also significantly longer among those treated with 3 or fewer chemotherapy regimens. For the 26 FLCL patients, the median age was 51 years and in 31% the indication for HDT was primary induction failure. For FLCL patients, the 4-year estimate of OS was 58% (95% CI, 37%-79%) and of DFS was 51% (95% CI, 30%-72%). Among the 17 patients with TFL, 13 (76%) transformed at first relapse, and only 6 patients (35%) achieved complete remission with salvage therapy prior to HDT. For TFL patients, the 4-year estimate of OS was 50% (95% CI, 24%-76%) and of DFS 49% (95% CI, 20%-78%). There were 3 occurrences of myelodysplasia (1 after treatment with TBI, 2 after BCNU treatment), yielding an estimated incidence of 7% (95% CI, 0%-16%) at 56 months. This analysis shows that relapsed FLGL patients treated with 3 or fewer different chemotherapy regimens show inferior survival. The HDT regimen containing FTBI appears to be superior to the BCNU-based regimen for relapsed FLGL, although longer follow-up is needed to evaluate late effects. Lastly, patients with TFL or induction failure and relapsed FLCL can achieve survival outcome comparable to those observed with the indolent follicular lymphomas.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Hematopoietic Stem Cell Transplantation , Lymphoma, Follicular/therapy , Adult , Aged , Carmustine/administration & dosage , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Disease-Free Survival , Etoposide/administration & dosage , Female , Humans , Lymphoma, Follicular/classification , Lymphoma, Follicular/complications , Male , Middle Aged , Neural Tube Defects/etiology , Prognosis , Recurrence , Remission Induction , Retrospective Studies , Survival Analysis , Transplantation, Autologous , Treatment Outcome , Whole-Body Irradiation
6.
J Gen Intern Med ; 16(5): 290-6, 2001 May.
Article in English | MEDLINE | ID: mdl-11359546

ABSTRACT

OBJECTIVE: To ascertain the views of physicians and physician leaders toward the legalization of physician-assisted suicide. DESIGN: Confidential mail questionnaire. PARTICIPANTS: A nationwide random sample of physicians of all ages and specialties, and all members of the American Medical Association (AMA) House of Delegates as of April 1996. MEASUREMENTS: Demographic and practice characteristics and attitude toward legalization of physician-assisted suicide. MAIN RESULTS: Usable questionnaires were returned by 658 of 930 eligible physicians in the nationwide random sample (71%) and 315 of 390 eligible physicians in the House of Delegates (81%). In the nationwide random sample, 44.5% favored legalization (16.4% definitely and 28.1% probably), 33.9% opposed legalization (20.4% definitely and 13.5% probably), and 22% were unsure. Opposition to legalization was strongly associated with self-defined politically conservative beliefs, religious affiliation, and the importance of religion to the respondent (P <.001). Among members of the AMA House of Delegates, 23.5% favored legalization (7.3% definitely and 16.2% probably), 61.6% opposed legalization (43.5% definitely and 18.1% probably), and 15% were unsure; their views differed significantly from those of the nationwide random sample (P <.001). Given the choice, a majority of both groups would prefer no law at all, with physician-assisted suicide being neither legal nor illegal. CONCLUSIONS: Members of the AMA House of Delegates strongly oppose physician-assisted suicide, but rank-and-file physicians show no consensus either for or against its legalization. Although the debate is sometimes adversarial, most physicians in the United States are uncertain or endorse moderate views on assisted suicide.


Subject(s)
American Medical Association , Attitude of Health Personnel , Organizational Policy , Physicians/psychology , Suicide, Assisted/psychology , Adult , Analysis of Variance , Ethics, Medical , Female , Humans , Logistic Models , Male , Middle Aged , Odds Ratio , Suicide, Assisted/legislation & jurisprudence , Surveys and Questionnaires , United States
7.
Stat Med ; 20(6): 841-58, 2001 Mar 30.
Article in English | MEDLINE | ID: mdl-11252007

ABSTRACT

Using decision theory, what is an appropriate sample size for a clinical trial, with a binary endpoint? We present a program, suitable for actual planning, which, with some extensions, implements Canner's solution to this question. Examples with a discussion are given. Implications of a Bayesian approach are discussed. Bayesian and Neyman--Pearson approaches are compared.


Subject(s)
Bayes Theorem , Randomized Controlled Trials as Topic/methods , Combined Modality Therapy , Folic Acid/therapeutic use , Humans , Kidney Diseases/drug therapy , Kidney Diseases/therapy , Renal Dialysis , Sample Size
8.
Am J Obstet Gynecol ; 184(2): 140-5, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11174493

ABSTRACT

OBJECTIVE: Results obtained with commercial testing kits for immunoglobulin M Toxoplasma antibodies may be inaccurate or may be inaccurately interpreted, which may influence whether a woman decides to terminate the pregnancy. This study was undertaken to determine whether confirmatory testing at a reference laboratory and communication of the results and an expert interpretation to the patient's physician would affect the rate of induced abortions among pregnant women with positive results of testing for immunoglobulin M Toxoplasma antibodies in outside laboratories. STUDY DESIGN: This was a retrospective cohort study of 811 consecutive pregnant women for whom the toxoplasma serologic profile was performed at a reference laboratory. Almost all the patients had been informed by their physicians that a result of a test for immunoglobulin M Toxoplasma antibodies performed in an outside laboratory was positive. Women were separated into those with a toxoplasma serologic profile result suggestive of a recently acquired infection (group 1) and those with a result suggestive of an infection acquired in the more distant past (group 2). Physician reports of induced abortions were used to determine rates of induced abortion in groups 1 and 2. RESULTS: Of the 811 women 321 (39.6%) were considered likely to have a recent infection (group 1) and 490 (60.4%) were considered likely to have a past infection (group 2). Physicians reported pregnancy outcomes for 433 (53.4%) of 811 women (65.1% and 45.7% in groups 1 and 2, respectively). Whereas 36 of 209 women in group 1 (17.2%) terminated the pregnancy, only 1 of 224 women in group 2 (0.4%) chose abortion (P <.001). CONCLUSION: Confirmatory serologic testing in a reference laboratory and communication of the results and their correct interpretation by an expert to the patient's physician decreased the rate of unnecessary abortions by approximately 50% among women for whom positive immunoglobulin M Toxoplasma test results had been reported by outside laboratories.


Subject(s)
Abortion, Induced/statistics & numerical data , Antibodies, Protozoan/blood , Immunoglobulin M/blood , Pregnancy Complications, Infectious/parasitology , Toxoplasma/immunology , Toxoplasmosis/diagnosis , Adult , Animals , Cohort Studies , Female , Gestational Age , Humans , Pregnancy , Pregnancy Complications, Infectious/diagnosis , Retrospective Studies
9.
Blood ; 97(2): 404-9, 2001 Jan 15.
Article in English | MEDLINE | ID: mdl-11154216

ABSTRACT

Advanced stage follicular small cleaved and mixed cell lymphoma is characterized by relapse from remission and survival ranging from 6 to 12 years. Because young patients have the greatest compromise in longevity, the efficacy and toxicity of high-dose radiochemotherapy and bone marrow transplantation after conventional chemotherapy was evaluated in a prospective phase II clinical trial. Thirty-seven patients in a minimal disease state after conventional chemotherapy received fractionated total body irradiation and high-dose etoposide and cyclophosphamide, followed by purged autologous bone marrow. A reference sample of 188 patients of similar age, stage, and histology managed at this institution before 1988 was identified for comparison of patient characteristics and outcomes. Compared with reference patients, transplant recipients had a higher tumor burden at diagnosis. With a median follow-up of 6.5 years, the estimated 10-year survival after transplantation was 86%. There was a single lymphoma death yielding a 10-year disease-specific survival of 97%. There were 2 early transplant-related deaths and 2 late acute leukemia deaths. Ten patients relapsed, one with microscopic disease only. High tumor burden at diagnosis and incomplete response to chemotherapy adversely influenced survival in the reference but not in the transplanted patients. The estimated risk of death of 14% and relapse of 30% at 10 years in our transplanted follicular lymphoma patients, the majority of whom had high tumor burdens, compares favorably with our observations in appropriately matched reference patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Transplantation/mortality , Lymphoma, Follicular/therapy , Actuarial Analysis , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/standards , Antineoplastic Combined Chemotherapy Protocols/toxicity , Cohort Studies , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Cyclophosphamide/standards , Cyclophosphamide/toxicity , Disease-Free Survival , Female , Follow-Up Studies , Humans , Lymphoma, Follicular/mortality , Male , Middle Aged , Neoplasm, Residual , Prednisone/administration & dosage , Prednisone/standards , Prednisone/toxicity , Prospective Studies , Radiotherapy, Adjuvant , Recurrence , Remission Induction , Survival Rate , Transplantation, Autologous/mortality , Vincristine/administration & dosage , Vincristine/standards , Vincristine/toxicity
10.
Child Abuse Negl ; 25(11): 1481-95, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11766012

ABSTRACT

OBJECTIVE: The study explores the prenatal Child Abuse Potential (pCAP) scores derived from the Child Abuse Potential Inventory administered to expectant adolescent mothers. The aim of the study was to assess the association of the pCAP scores with maternal negative prenatal behaviors, and evaluate the contribution of the pCAP scores to neonatal morbidity. METHOD: The pCAP scores, demographic data, and self-report on prenatal behaviors were obtained during the second half of the pregnancy in a sample of 45 poor single adolescent mothers. A pediatrician blind to the prenatal data reviewed the neonatal records to assess neonatal morbidity. Maternal prenatal records were reviewed for obstetric risk assessment by an obstetrician who was blind to the rest of the data. The relations among the pCAP scores, prenatal behaviors, and neonatal morbidity were analyzed. RESULTS: In the prenatal period, the pCAP scores were positively correlated with self-reported prenatal smoking and substance use. The multiple linear regression analysis showed that the pCAP scores significantly contributed to neonatal morbidity independently of obstetric risk factors. CONCLUSIONS: The Child Abuse Potential scores obtained during pregnancy in poor single adolescent mothers reflect domains of maternal functioning that are associated with negative prenatal behaviors and appear to be important for predicting neonatal morbidity. Further studies are warranted to validate the prenatal use of the Child Abuse Potential Inventory.


Subject(s)
Child Abuse/psychology , Pregnancy in Adolescence/psychology , Adolescent , California/epidemiology , Child Abuse/mortality , Female , Humans , Infant , Infant, Newborn , Pregnancy , Pregnancy Outcome/psychology , Pregnancy Trimester, Third , Prenatal Care
11.
Anim Reprod Sci ; 58(3-4): 169-95, 2000 Mar 15.
Article in English | MEDLINE | ID: mdl-10708894

ABSTRACT

In this paper, aspects of reproductive physiology and endocrinology, as well as sexual behaviour in South American camelids are reviewed. Because of the many unique features of reproduction in these animals, the application of advanced breeding techniques that are routinely used in other domestic species has been slow and, in some cases, are not applicable. Relatively high embryonic loss and the capacity to carry only one offspring at a time limit production in females. Furthermore, some 20% of females do not conceive following mating. Research is needed to elucidate the causes of embryonic loss, particularly in relation to the preferential location of embryos in the left uterine horn and the apparent differential luteolytic activity of the two uterine horns. A fuller understanding of the endocrine changes and mechanisms accompanying folliculogenesis, estrus, induction of ovulation and luteal regression may led to treatments that provide better control of ovulation and enhance the quality and viability of eggs shed. In the male, the hormonal interactions involved in facilitating libido need to be established and the underlying causes of declining libido resulting from continued exposure to estrous females, identified. More importantly, there is a need to develop a routine method to collect semen from animals on farm, or in studs. Deficiencies in this area have long hampered the evaluation of sires through proper assessment of their semen quality and in the application of artificial insemination. In addition, establishment of techniques to freeze semen from these species has obvious advantages for breeding, including crossbreeding between species to improve products such as fibre and to assist in preservation of some of the more endangered New World camelids.


Subject(s)
Camelids, New World/physiology , Reproduction/physiology , Animals , Female , Male , Reproductive Techniques/veterinary , Seasons , Sexual Maturation
12.
Cancer Chemother Pharmacol ; 45(4): 305-11, 2000.
Article in English | MEDLINE | ID: mdl-10755319

ABSTRACT

PURPOSE: The consequences of using cyclosporine (CsA) therapy to modulate P-glycoprotein-mediated multidrug resistance include increased myelosuppression, hyperbilirubinemia, and altered disposition of the cytotoxin. The purpose of this study was to analyze further the relationship between the degree of leukopenia, and etoposide pharmacokinetic factors. METHODS: Each patient initially received intravenously-administered etoposide alone (150-200 mg/m2/d x 3). Later it was given in combination with CsA administered at escalating loading doses (range 2-7 mg/kg) as a 2 hour intravenous (IV) infusion followed by a 3 day continuous infusion, at doses ranging from 5 to 21 mg/ kg/day. Serial plasma etoposide concentration-time samples were assayed by high-performance liquid chromatography (HPLC). The area under the curve (AUC) of unbound etoposide was calculated from the total plasma etoposide AUC using a previous published equation [22] where % unbound etoposide = (1.4 x total bilirubin) - (6.8 x serum albumin) + 34.4. The percent decrease in white blood cell (WBC) count and the total or unbound etoposide AUC relationship was fitted to a sigmoid Emax model adapted for paired observations, where: % Decrease in WBC count =E(max) x PDRV(H+Z x delta)/(PDRV50 + Z x beta) + PDRVH + Z x delta In this equation, Z was the variable describing the two treatment groups (0 = no CsA and 1 = CsA). The fitted parameters were PDRV50, the pharmacodynamic response variable (PDRV) producing 50% of the maximal response; parameter beta, which describes the effect of the treatment group on the PDRV50; parameter H (Hill constant), which defines the slope of the response curve and parameter delta, which describes the effect of the treatment group on parameter H. RESULTS: CsA at a median concentration of 1,938 microg/ml resulted in a median increase in the total plasma etoposide AUC by 103% and the calculated unbound plasma etoposide AUC by 104%. This paralleled a 12% greater median percent decrease in WBC count during etoposide + CsA treatment (72% vs. 84%, P = 0.03). The percent decrease in WBC count and total or unbound etoposide AUC relationship was fitted to the sigmoid Emax model. The model using the unbound etoposide AUC described the data adequately (r = 0.790) and was precise, with a mean absolute error of 6.4% (95% confidence interval: -4.9, 7.8). The fitted parameter-estimates suggested that at equivalent unbound etoposide AUC values above 10 microg x h/ml, the sigmoid Emax model predicted a 5% greater WBC count suppression when CsA was added to the treatment regimen. CONCLUSION: These findings suggest that a small degree of the enhanced myelosuppression observed with CsA combined with etoposide might be attributable to inhibition of P-glycoprotein in bone marrow precursor cells. However, the majority of the effect observed appears to be due to pharmacokinetic interactions, which result in increases in unbound etoposide.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacokinetics , Cyclosporine/pharmacology , Etoposide/pharmacokinetics , Genes, MDR/genetics , Immunosuppressive Agents/pharmacology , Adult , Aged , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/adverse effects , Area Under Curve , Bone Marrow Diseases/blood , Bone Marrow Diseases/chemically induced , Chromatography, High Pressure Liquid , Cyclosporine/administration & dosage , Drug Resistance, Neoplasm , Erythroid Precursor Cells/drug effects , Etoposide/administration & dosage , Etoposide/adverse effects , Female , Humans , Immunosuppressive Agents/administration & dosage , Infusions, Intravenous , Leukocyte Count/drug effects , Leukopenia/chemically induced , Male , Middle Aged
13.
Stat Med ; 18(22): 3075-88, 1999 Nov 30.
Article in English | MEDLINE | ID: mdl-10544307

ABSTRACT

Kernel-based methods for the smooth, non-parametric estimation of the hazard function have received considerable attention in the statistical literature. Although the mathematical properties of the kernel-based hazard estimators have been carefully studied, their statistical properties have not. We reviewed various kernel-based methods for hazard function estimation from right-censored data and compared the statistical properties of these estimators through computer simulations. Our simulations covered seven distributions, three levels of random censoring, four types of bandwidth functions, two sample sizes and three types of boundary correction. We conducted a total of 504 simulation experiments with 500 independent samples each. Our results confirmed the advantages of two recent innovations in kernel estimation - boundary correction and locally optimal bandwidths. The median relative improvement (decrease) in mean square error over fixed-bandwidth estimators without boundary correction was 3 per cent for fixed-bandwidth estimators with left boundary correction, 52 per cent locally optimal bandwidths without boundary correction, and 66 per cent for locally optimal bandwidths with left boundary correction. The locally optimal bandwidth estimators with left boundary correction also outperformed three previously published and publicly available algorithms, with median relative improvements in mean square error of 31 per cent, 77 per cent and 80 per cent.


Subject(s)
Computer Simulation , Proportional Hazards Models , Humans
14.
Stat Med ; 18(22): 3137-51, 1999 Nov 30.
Article in English | MEDLINE | ID: mdl-10544312

ABSTRACT

This paper describes two asymptotic methods for sample size and power calculation for hypothesis testing. Both methods assume that the distribution of the likelihood ratio is approximately distributed as a central chi(2) distribution under the null hypothesis and as a non-central chi(2) under the alternative hypothesis. The approximation to the non-centrality parameter differs between the methods. It is shown how these methods can be automatically extended from constraints setting parameters to constant values to constraints positing equality of parameters. Two very simple examples are presented; one demonstrates that the information method can produce arbitrarily incorrect results. Four more comprehensive examples are then discussed. In addition to demonstrating the wide range of applicability of these methods, the examples illustrate techniques that may be used in cases in which there is insufficient initial information available to perform a realistic calculation. The availability of a computer implementation of these methods in S-plus is announced, as are routines for computing the cumulative distribution function of the non-central chi(2) and its inverse.


Subject(s)
Computer Simulation , Likelihood Functions , Models, Statistical , Sample Size , Counseling , Humans , Nicotine , Plants, Toxic , Software , Tobacco, Smokeless
15.
Med Care ; 37(1): 5-14, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10413387

ABSTRACT

OBJECTIVES: This study evaluated the effectiveness (changes in health behaviors, health status, and health service utilization) of a self-management program for chronic disease designed for use with a heterogeneous group of chronic disease patients. It also explored the differential effectiveness of the intervention for subjects with specific diseases and comorbidities. METHODS: The study was a six-month randomized, controlled trial at community-based sites comparing treatment subjects with wait-list control subjects. Participants were 952 patients 40 years of age or older with a physician-confirmed diagnosis of heart disease, lung disease, stroke, or arthritis. Health behaviors, health status, and health service utilization, as determined by mailed, self-administered questionnaires, were measured. RESULTS: Treatment subjects, when compared with control subjects, demonstrated improvements at 6 months in weekly minutes of exercise, frequency of cognitive symptom management, communication with physicians, self-reported health, health distress, fatigue, disability, and social/role activities limitations. They also had fewer hospitalizations and days in the hospital. No differences were found in pain/physical discomfort, shortness of breath, or psychological well-being. CONCLUSIONS: An intervention designed specifically to meet the needs of a heterogeneous group of chronic disease patients, including those with comorbid conditions, was feasible and beneficial beyond usual care in terms of improved health behaviors and health status. It also resulted in fewer hospitalizations and days of hospitalization.


Subject(s)
Chronic Disease/therapy , Disease Management , Health Status , Hospitalization/statistics & numerical data , Patient Education as Topic/organization & administration , Self Care/methods , Adult , Aged , Aged, 80 and over , Comorbidity , Female , Health Behavior , Humans , Male , Middle Aged , Program Evaluation , Surveys and Questionnaires , United States
16.
Circulation ; 100(1): 61-6, 1999 Jul 06.
Article in English | MEDLINE | ID: mdl-10393682

ABSTRACT

BACKGROUND: Coronary artery disease occurs in an accelerated fashion in the donor heart after heart transplantation (TxCAD), but the cause is poorly understood. The risk of developing TxCAD is increased by cytomegalovirus (CMV) infection and decreased by use of calcium blockers. Our group observed that prophylactic administration of ganciclovir early after heart transplantation inhibited CMV illness, and we now propose to determine whether this therapy also prevents TxCAD. METHODS AND RESULTS: One hundred forty-nine consecutive patients (131 men and 18 women aged 48+/-13 years) were randomized to receive either ganciclovir or placebo during the initial 28 days after heart transplantation. Immunosuppression consisted of muromonab-CD3 (OKT-3) prophylaxis and maintenance with cyclosporine, prednisone, and azathioprine. Mean follow-up time was 4.7+/-1.3 years. In a post hoc analysis of this trial designed to assess efficacy of ganciclovir for prevention of CMV disease, we compared the actuarial incidence of TxCAD, defined by annual angiography as the presence of any stenosis. Because calcium blockers have been shown to prevent TxCAD, we analyzed the results by stratifying patients according to use of calcium blockers. TxCAD could not be evaluated in 28 patients because of early death or limited follow-up. Among the evaluable patients, actuarial incidence of TxCAD at follow-up (mean, 4.7 years) in ganciclovir-treated patients (n=62) compared with placebo (n=59) was 43+/-8% versus 60+/-10% (P<0.1). By Cox multivariate analysis, independent predictors of TxCAD were donor age >40 years (relative risk, 2.7; CI, 1.3 to 5.5; P<0.01) and no ganciclovir (relative risk, 2.1; CI, 1.1 to 5.3; P=0.04). Stratification on the basis of calcium blocker use revealed differences in TxCAD incidence when ganciclovir and placebo were compared: no calcium blockers (n=53), 32+/-11% (n=28) for ganciclovir versus 62+/-16% (n=25) for placebo (P<0.03); calcium blockers (n=68), 50+/-14% (n=33) for ganciclovir versus 45+/-12% (n=35) for placebo (P=NS). CONCLUSIONS: TxCAD incidence appears to be lower in patients treated with ganciclovir who are not treated with calcium blockers. Given the limitations imposed by post hoc analysis, a randomized clinical trial is required to address this issue.


Subject(s)
Antiviral Agents/therapeutic use , Coronary Artery Disease/prevention & control , Ganciclovir/therapeutic use , Heart Transplantation/adverse effects , Postoperative Complications/prevention & control , Actuarial Analysis , Adult , Aged , Antibodies, Viral/blood , Calcium Channel Blockers/therapeutic use , Cause of Death , Coronary Artery Disease/epidemiology , Coronary Artery Disease/etiology , Coronary Artery Disease/virology , Cytomegalovirus/immunology , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/drug therapy , Cytomegalovirus Infections/epidemiology , Female , Follow-Up Studies , Humans , Immunosuppression Therapy/adverse effects , Incidence , Male , Middle Aged , Postoperative Complications/drug therapy , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Postoperative Complications/virology , Proportional Hazards Models , Reoperation , Risk , Seroepidemiologic Studies , Treatment Outcome
18.
Neuroepidemiology ; 17(6): 318-29, 1998.
Article in English | MEDLINE | ID: mdl-9778598

ABSTRACT

The decline of neurological and neuromuscular function with age in older women and in subgroups of older women with selected risk factors for poor function is described using cross- sectional analyses of data on 8,080 women from the multicenter Study of Osteoporotic Fractures. All twelve performance-based tests of muscle strength, balance, gait, somatosensory discrimination and reaction time declined with increasing age. On a percentage scale, vibration threshold declined the most rapidly with age. Participants who were smokers, physically inactive, nonconsumers of alcohol, diabetics and more frequent fallers had poorer age-adjusted performance than those without these attributes. However, with a few exceptions, the rate of decline in performance with age for those with and without these characteristics did not differ significantly.


Subject(s)
Aging/physiology , Nervous System Physiological Phenomena , Osteoporosis, Postmenopausal/physiopathology , Aged , Aged, 80 and over , Female , Gait , Hand Strength/physiology , Humans , Muscle, Skeletal/physiopathology , Neurologic Examination , Osteoporosis, Postmenopausal/epidemiology , Reaction Time/physiology , Risk Factors , Sensory Thresholds/physiology , Surveys and Questionnaires , Touch/physiology , United States/epidemiology
19.
Endocrinology ; 139(4): 2007-14, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9528988

ABSTRACT

The effects of neonatal immunization against GnRH were studied in sheep after they had reached adulthood (3-4 yr) and the antibody titers had fallen to undetectable levels. The immunized animals had small gonads, and the females did not have large follicles (>3 mm) or corpora lutea in their ovaries. Compared with controls, the immunized animals had low or nondetectable levels of LH and FSH in peripheral plasma, and the immunized animals generally failed to respond to a single i.v. GnRH challenge. After ovariectomy, the control ewes, but not the immunized ewes, showed an elevation in plasma LH and FSH levels. The sampling of hypophysial portal blood, with a newly described method, showed that the secretion of GnRH was reduced in the immunized animals, but the amount of GnRH in the median eminence was similar in the control and immunized ewes. The pituitary content of LH and FSH was reduced in the immunized ewes as was messenger RNA for the gonadotropin subunits and the GnRH receptor. These data indicate that neonatal immunization does not affect the synthesis of GnRH in adulthood but reduces the secretion of GnRH, causing long-term sterility in these animals.


Subject(s)
Animals, Newborn , Gonadotropin-Releasing Hormone/immunology , Gonadotropin-Releasing Hormone/metabolism , Immunization , Animals , Female , Follicle Stimulating Hormone/blood , Follicle Stimulating Hormone/genetics , Gonadotropin-Releasing Hormone/analysis , Hypogonadism/etiology , Hypogonadism/physiopathology , Luteinizing Hormone/blood , Luteinizing Hormone/genetics , Male , Median Eminence/chemistry , Ovarian Follicle/growth & development , Ovariectomy , Ovary/growth & development , Pituitary Gland/chemistry , RNA, Messenger/analysis , Sheep
20.
Reprod Fertil Dev ; 10(7-8): 659-65, 1998.
Article in English | MEDLINE | ID: mdl-10612473

ABSTRACT

The direct transfer of recombinant DNA to embryos is conceptually a powerful method for the manipulation of the genetic potential of domestic animals, but in practice the technology has yet to fulfil its promise. In this paper, two examples are given of research utilising direct genetic manipulation, both of which are aimed at increasing aspects of productivity in sheep. The first of these involves the modification of the growth hormone status of sheep by the use of the ovine growth hormone gene, the regulation of which has been altered by the use of an ovine metallothionein promoter. While there has been a large amount of research already conducted in this area by many groups, our recent results provide one of the first demonstrations that this approach can increase the growth rates of sheep while maintaining the animals in good health. The second project involves the modification of intermediary metabolism in sheep by the introduction of the cysteine biosynthetic pathway. The results to date demonstrate that it is possible to change intermediary metabolism in animals using our approach but that there are species-specific requirements that must be satisfied in order to make the approach a practical method for improving animal productivity.


Subject(s)
Animals, Genetically Modified/genetics , Nuclear Transfer Techniques , Sheep/genetics , Animals , Animals, Domestic , Animals, Genetically Modified/growth & development , Animals, Genetically Modified/metabolism , Body Weight/genetics , Cell Nucleus/genetics , Cysteine/biosynthesis , Female , Gene Transfer Techniques , Growth Hormone/genetics , Male , Metallothionein/genetics , Organ Size/genetics , Sheep/growth & development , Sheep/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...